Batoclimab is under clinical development by Immunovant and currently in Phase III for Graves’ Ophthalmopathy. According to GlobalData, Phase III drugs for Graves’ Ophthalmopathy have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Batoclimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Batoclimab overview

Batoclimab is under development for the treatment of myasthenia gravis (MG), Graves' ophthalmopathy, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves disease (GD). It is a fully human monoclonal antibody IgG1 targeting the Fc neonatal receptor (FcRn). It is administered subcutaneously and developed based on OmniAb technology. 

It was under development for warm autoimmune hemolytic anemia, neuromyelitis optica (NMO), lupus nephritis (LN), pemphigus vulgaris, idiopathic thrombocytopenic purpura (ITP) and membranous glomerulonephritis.

For a complete picture of Batoclimab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.